E-Learning

The so-called “Trump Trade 2.0” appears to be impacting everything from stocks to cryptocurrency.

Needham analyst Gerald Pascarelli initiated coverage on Celsius Holdings, Inc. (NASDAQ:CELH) with a Buy rating and a price target of $38. The analyst says that as the third-largest player in energy drinks, CELH is positioned to benefit from a healthier category rebound and growing demand for zero-sugar products, creating a favorable environment for revenue acceleration alongside easier year-over-year comparisons. The analyst writes that while the company recently saw its first year-over-year sha

Here are the stocks making the biggest market moves midday.

AMC Entertainment announced it would have another stock sale, offering 50 million shares through Goldman Sachs, and shares sank nearly 10%.

Wall Street firms spend a pretty penny on executive salaries and compensation, especially for those at the helm.

US benchmark equity indexes were mixed intraday after official data showed the economy added more jo

An inflation report in the coming week will test the strength of the record-setting U.S. stocks rally and provide a crucial piece of data that could factor into the Federal Reserve's plans for rate cuts. The rosy backdrop for stocks is underscored by expectations of further Fed interest rate cuts at the same time the economy remains resilient. However, data on consumer prices due on Wednesday could threaten the upbeat narrative if inflation rates are above expectations, posing a challenge for high-flying stocks.

WASHINGTON (Reuters) -U.S. job growth surged in November after being severely hindered by hurricanes and strikes, but a rise in the unemployment rate to 4.2% pointed to an easing labor market that should allow the Federal Reserve to cut interest rates again this month. The labor market's resilience is driving the economy through strong consumer spending, with the closely watched employment report from the Labor Department on Friday showing solid wage growth last month. "The report should soothe bears and bulls alike," said Scott Anderson, chief U.S. economist at BMO Capital Markets.

On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE (NASDAQ:BNTX). The data were presented in an oral session at the 2024 European Society of Medical Oncology Asia Annual Meeting in Singapore and showed encouraging antitumor activity alongside a manageable safety profile in heavily pretreated patients with locally advanced or metastatic solid tumors. The ongoing Phase 1/2a trial analysis included 277 part

The Cboe Volatility Index hasn’t been this low in months.